GSK3β-sparing DYRK1A kinase inhibitor

orally efficacious in proliferation model, but non-specific proliferation observed

from cellular phenotypic screen and opt.

J. Med. Chem. Feb. 20, 2020

Novartis (GNF), San Diego, CA

GNF2133 (Novartis (GNF) oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks